REGENXBIO

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.

CEO

Curran M. Simpson

CEOCurran M. Simpson

Employees

353

Employees353

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2008

Founded2008

Employees

353

Employees353

RGNX Key Statistics

Market cap

415.65M

Market cap415.65M

Price-Earnings ratio

-2.78

Price-Earnings ratio-2.78

Dividend yield

—

Dividend yield—

Average volume

576.36K

Average volume576.36K

High today

$8.84

High today$8.84

Low today

$8.23

Low today$8.23

Open price

$8.77

Open price$8.77

Volume

440.59K

Volume440.59K

52 Week high

$15.36

52 Week high$15.36

52 Week low

$5.04

52 Week low$5.04

Analyst ratings

92%

of 13 ratings

Buy

92.3%

Hold

7.7%

Sell

People also own

Based on the portfolios of people who own RGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

CRISPR

Viking Therapeutics

Intellia Therapeutics

Plug Power

Moderna